Treatment with CNM-Au8 significantly delayed clinical worsening in people with amyotrophic lateral sclerosis (ALS), according to new exploratory analyses from the therapy’s arm of the HEALEY ALS platform trial. The experimental therapy, from Clene Nanomedicine, had previously been found to reduce the risk of death by more…
AviadoBio has entered into a worldwide exclusive agreement to develop and commercialize Neurgain Technologies’ new technique to deliver gene therapies for diseases that affect the spinal cord. The approach will be used at first to deliver AviadoBio’s investigational gene therapies for amyotrophic lateral sclerosis (ALS). It involves…
RAG-17, an investigational therapy from Ractigen Therapeutics to treat amyotrophic lateral sclerosis (ALS), has been designated an orphan drug by the U.S. Food and Drug Administration (FDA). Orphan drug status is given to medicines intended to treat life-threatening or chronically debilitating diseases that affect fewer than 200,000 individuals…
Amyotrophic lateral sclerosis (ALS) patients treated earlier with CNM-Au8 in a clinical trial experienced a significantly slower disease progression than those who started treatment nine months later. These latest findings from the RESCUE-ALS Phase 2 trial (NCT04098406) and its open-label extension (OLE) study (NCT05299658) add to earlier reports that…
Levels of the TDP-43 protein in spinal fluid show promise as biomarkers for amyotrophic lateral sclerosis (ALS) and may aid in diagnosing the neurological disease, according to a new review of several published studies. That review discovered that these protein levels are increased in…
Enrollment is still ongoing for a Phase 2 clinical trial testing the safety and efficacy of Corcept Therapeutics‘ cortisol modulator, called dazucorilant, in people with amyotrophic lateral sclerosis (ALS). The DAZALS trial (NCT05407324), launched in November 2022, is expected to enroll an estimated 198 adults with…
Note: This story was updated March 10, 2023, to correct a secondary headline to note the therapy was tracked for less than a year. The story also clarifies the timing of results from a Phase 3 clinical trial and that edaravone is believed to reduce oxidative stress. Radicava ORS, an…
Pridopidine, an oral small molecule, failed to meet its primary goal of improving physical function across amyotrophic lateral sclerosis (ALS) patients who took part in a Phase 2/3 clinical trial. Changes in secondary endpoints measuring muscle strength and respiratory function also did not significantly differ between people taking pridopidine…
To help those who have lost their ability to speak easily, Georgia Southern University’s RiteCare Center for Communications Disorders again is recruiting students, faculty, and staff members to make recordings for submission to a voice bank. The center’s third annual Voice Drive, which runs through May 2, is…
Kadimastem is planning a Phase 2a clinical trial to test if repeat dosing of AstroRx, its investigational therapy for amyotrophic lateral sclerosis (ALS), can continuously delay the disease’s progression. The study will investigate every three-month dosing after findings from an earlier Phase 1/2 trial (NCT03482050) showed a…
Get regular updates to your inbox.